# novonesis

# Trading by management and close relations of management

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B.

	ing managerial responsibilities/person closely associated			
a)	Name	Claus Crone Fuglsang		
2.	Reason for the notification			
a)	Position/status	Executive Vice President, Chief Scientific Officer		
b)	Initial notification/Amendment	Initial notification		
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	Novozymes A/S, part of Novonesis Group		
b)	LEI	529900T6WNZXD2R3JW38		
	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
4.	type of transaction; (iii) each o	ection to be repeated for (i) each type of instrument; (ii) each date; and (iv) each place where transactions have been		
<b>4.</b> a)	Details of the transaction(s): s type of transaction; (iii) each o conducted Description of the financial instrument, type of instrument	ection to be repeated for (i) each type of instrument; (ii) each date; and (iv) each place where transactions have been B-shares		
	type of transaction; (iii) each of conducted Description of the financial	late; and (iv) each place where transactions have been		
a)	type of transaction; (iii) each of conducted Description of the financial instrument, type of instrument	date; and (iv) each place where transactions have been B-shares		
	type of transaction; (iii) each of conducted Description of the financial instrument, type of instrument Identification code	date; and (iv) each place where transactions have been         B-shares         DK0060336014         Exercise of share options (purchase) from incentive program         Volume       Price (DKK)		
a) b)	type of transaction; (iii) each of conducted Description of the financial instrument, type of instrument Identification code Nature of the transaction	date; and (iv) each place where transactions have been         B-shares         DK0060336014         Exercise of share options (purchase) from incentive program         Volume       Price (DKK)		
a) b) c)	type of transaction; (iii) each of conducted         Description of the financial instrument, type of instrument         Identification code         Nature of the transaction         Price(s) and volume(s)	date; and (iv) each place where transactions have been         B-shares         DK0060336014         Exercise of share options (purchase) from incentive program         Volume       Price (DKK)		
a) b) c)	type of transaction; (iii) each of conducted         Description of the financial instrument, type of instrument         Identification code         Nature of the transaction         Price(s) and volume(s)         Aggregated information         -       Aggregated volume	date; and (iv) each place where transactions have been         B-shares         DK0060336014         Exercise of share options (purchase) from incentive program         Volume       Price (DKK)         10,277       274.90         10,277 shares		

### September 16, 2024

Company announcement No. 37

## Contact information

Tobias Bjorklund +45 3077 8682 tobb@novonesis.com

Anders Enevoldsen +45 5350 1453 adev@novonesis.com

#### About Novonesis

Novonesis is a global leading biosolutions company transforming the way we all produce, consume and live. In more than 30 industries our biosolutions are helping companies meet their business needs and the needs of our planet. Our 10,000 people worldwide work closely with our partners and customers to challenge conventional thinking and transform business with biology.

CVR number: 10 00 71 27 - LEI: 529900T6WNZXD2R3JW38

Novozymes A/S, part of Novonesis Group Krogshoejvej 36 2880 Bagsvaerd Denmark



a)	Name	Claus Crone Fuglsang		
2.	Reason for the notification			
a)	Position/status	Executive Vice President, Chief Scientific Officer		
b)	Initial notification/Amendment	Initial notification		
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	Novozymes A/S, part of Novonesis Group		
b)	LEI	529900T6WNZXD2R3JW38		
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a)	Description of the financial instrument, type of instrument	B-shares		
	Identification code	DK0060336014		
b)	Nature of the transaction	Sale of shares		
c)	Price(s) and volume(s)	See appendix		
d)	Aggregated information - Aggregated volume - Price - Weighted average	10,277 shares 4,811,274.40 DKK 468.16 DKK		
e)	Date of the transaction	September 13, 2024		

Trading by management and close relations of management. Company announcement No. 37

### Appendix

Date	Trading location	Quantity	Executed price
Sep 13, 2024	Off Exchange	4,478 shares	DKK 468.20
Sep 13, 2024	Off Exchange	152 shares	DKK 468.00
Sep 13, 2024	Off Exchange	354 shares	DKK 468.00
Sep 13, 2024	CITIGROUP GLOBAL MARKETS EUROPE AG - EMEA TRADING	72 shares	DKK 467.90
Sep 13, 2024	Off Exchange	207 shares	DKK 468.00
Sep 13, 2024	Off Exchange	5,000 shares	DKK 468.15
Sep 13, 2024	CITIGROUP GLOBAL MARKETS EUROPE AG - EMEA TRADING	14 shares	DKK 468.00